共 50 条
- [31] Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (IaCSCC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Migden, Michael RobertKhushalani, Nikhil I.Chang, Anne Lynn S.Rischin, DannySchmults, Chrysalyne D.Hernandez-Aya, Leonel FernandoMeier, Friedegund ElkeSchadendorf, DirkGuminski, Alexander DavidHauschild, AxelWong, Deborah J. L.Daniels, Gregory A.Berking, CarolaJankovic, VladimirStankevich, ElizabethBooth, JocelynLi, SiyuLowy, IsraelFury, Matthew G.Lewis, Karl D.
- [32] Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD1 monoclonal antibody, in patients with advanced malignanciesCANCER RESEARCH, 2017, 77Song, XuyangGao, XizheZheng, BoBlack, ChelseaGribbin, MatthewKarakunnel, JoysonRoskos, LorinNarwal, Rajesh
- [33] Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignanciesCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (03) : 373 - 382Song, XuyangKhan, Anis A.Zhou, DiansongElgeioushi, NairouzWalcott, FarzanaRen, SongGibbs, Megan
- [34] Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignanciesCancer Chemotherapy and Pharmacology, 2022, 89 : 373 - 382Xuyang SongAnis A. KhanDiansong ZhouNairouz ElgeioushiFarzana WalcottSong RenMegan Gibbs
- [35] Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I studyANNALS OF ONCOLOGY, 2018, 29He, A. R.Weiss, G. J.Falchook, G.Yee, N. S.Gil-Martin, M.Shahda, S.Moreno, V.Brana, I.Crittenden, M.Formenti, S.Al-Rajabi, R.Papadopoulos, K. P.Pishvaian, M. J.Stankevich, E.Feng, M.Li, J.Mathias, M.Kroog, G.Lowy, I.Fury, M. G.
- [36] Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Moore, Kathleen N.Dresher, CharlesLiu, JoyceO'Malley, David M.Wang, Edward WengeWang, Judy Sing-ZanSubbiah, VivekWilky, Breelyn A.Yuan, GuojunDupont, Christopher D.Gonzalez, Ana M.Savitsky, DavidCoulter, SaraShebanova, OlgaDow, EdProscurshim, IgorBuell, JenniferStein, Robert BenjaminYoussoufian, Hagop
- [37] Population pharmacokinetics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumorsEUROPEAN JOURNAL OF CANCER, 2015, 51 : S28 - S28Song, X.Pak, M.Chavez, C.Liang, M.Lu, H.Blake-Haskins, J. A.Robbins, P. B.Jin, X.Gupta, A.Roskos, L.Narwal, R.
- [38] Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2016, 34 (05) : 596 - 603Mizugaki, HidenoriYamamoto, NoboruMurakami, HaruyasuKenmotsu, HirotsuguFujiwara, YutakaIshida, YoshimasaKawakami, TomohisaTakahashi, Toshiaki
- [39] Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumorsInvestigational New Drugs, 2016, 34 : 596 - 603Hidenori MizugakiNoboru YamamotoHaruyasu MurakamiHirotsugu KenmotsuYutaka FujiwaraYoshimasa IshidaTomohisa KawakamiToshiaki Takahashi
- [40] A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation resultsJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Lakhani, Nehal J.Hamid, OmidBrana, IreneLostes-Bardaji, M. JuliaGajate, PabloLopez-Criado, Maria PilarSwiecicki, Paulde Miguel, Maria J.Gil-Martin, MartaMoreno, VictorMuller, Aixa Elena SoyanoOrtiz, Ana GonzalezSun, DylanModi, DimpleZheng, WenjunJankovic, VladimirSalvati, MarkFury, Matthew G.Cristea, Mihaela C.